Medicare Advantage
Advanced Search
MPIssuedDate
  
MPNewsFlashTopicPub
MPNFSortOrder
  
MPPolicyPageName
  
MPPurposePub
Title
  
MPPageName
  
5/12/2023
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage Members (Updated May 12, 2023)
0.1

The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage members. Additionally, this Company document identifies when coverage is provided for clinical purposes, and the not co​vered instances such as public health surveillance and screening. 

Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage Members (Updated May 12, 2023)bbb097d3-f300-4610-a41e-d4d86cbcc5e2
5/12/2023
Coverage of the COVID-19 Vaccination for Medicare Advantage Members (Updated on May 12, 2023)
0.1

This communication provides notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines and administration of the vaccines​ that have been granted US Food and Drug Administration (FDA) approval and/or have received an Emergency Use Authorization (EUA). Coverage of SARS-CoV-2 vaccines granted an EUA shall remain in effect during the applicable EUA declaration, unless the specific EUA for a SARS-CoV-2 vaccine has been terminated and/or revoked. 

Coverage of the COVID-19 Vaccination for Medicare Advantage Members (Updated on May 12, 2023)5f8d9ab3-d9a5-436c-bd59-3b49c710151b
5/12/2023
Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Medicare Advantage Members (Updated May 12, 2023)
0.1
The purpose of this document is to communicate the Company's coverage position for Pharmaceutical Prophylaxis and Treatments of COVID-19 for Medicare Advantage members. This communication addresses pharmaceutical prophylaxis and treatments of COVID-19 that have been granted FDA approval and/or have received an Emergency Use Authorization. Coverage for the pharmaceutical treatments granted an EUA shall remain in effect during the applicable EUA declaration, unless the specific EUA for a treatment have been terminated and revoked.
Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Medicare Advantage Members (Updated May 12, 2023)07d6ad3a-83ca-4ec4-a3b4-4479edfe9ead
5/8/2023
Preventive Coverage of Prostate Cancer Screening for Medicare Advantage Members (Issued May 8, 2023; Retroactively effective to January 1, 2023)
0.1
The purpose of this document is to communicate the preventive coverage of ​procedure code 0359U for prostate cancer screening with the prostate-specific antigen blood test for Medicare Advantage members in accordance with CMS guidance issued March 2023 and retroactively effective to January 1, 2023. 
Preventive Coverage of Prostate Cancer Screening for Medicare Advantage Members (Issued May 8, 2023; Retroactively effective to January 1, 2023)6541113f-ecf0-48df-b3d6-eaf9eab6a56e
4/1/2023
04/01/2023 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products
0.1
The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 04/01/2023, unless otherwise noted.  For more information related to these services, please refer to specific policies when applicable.​​​​​​​
04/01/2023 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products7d23c17b-b8a8-4c3d-9bde-cbe6aed530a2
3/3/2023
Preventive Coverage of Chlamydia and Gonorrhea Screening for Medicare Advantage Members (Retroactively Effective to 10/01/2022)
0.1
The purpose of this document is to communicate the preventive coverage of chlamydia and gonorrhea screening for Medicare Advantage members. 
Preventive Coverage of Chlamydia and Gonorrhea Screening for Medicare Advantage Members (Retroactively Effective to 10/01/2022)35f6c3ac-47e9-40fb-acca-5e904224f2b6
11/7/2022
Laboratory Testing, Vaccination, and Treatment for Monkeypox for Medicare Advantage Members (Updated November 7, 2022)
0.1
The purpose of this document is to communicate the Company's coverage positions for laboratory testing, vaccination, and treatment for monkeypox.

Laboratory Testing, Vaccination, and Treatment for Monkeypox for Medicare Advantage Members (Updated November 7, 2022)7b66a316-16f5-4b57-a892-851f122bac00
4/29/2020
Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-19 (Updated December 15, 2021)
1
The purpose of this News Article is to provide advance notice regarding direct supervision requirements for Incident to services performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in response to Coronavirus Disease 2019 (COVID-19).
Direct Supervision Requirements for Incident to Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs) in Response to COVID-194FDDC2AFA5B549C885258558007D7B93
Connect with Us

2023 Independence Blue Cross

Independence Blue Cross is a subsidiary of Independence Health Group, Inc. — independent licensees of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.